Intervention Studies for the metabolite Theophylline with food phytochemical Theophylline
| Food Phytochemical | Metabolite | Species | Biofluids | Origin | Dietary Source Description | Dietary Source Classification | Total Number of Subjects | Description of Population | Ingested Amount | Single/Multiple Dose | Duration of the Study | Tmax (h) | Cmax (nM) | AUC (nM/h) | Time covered by AUC (h) | t 1/2 (h) | % of 24h Urinary Excretion | Excreted Amount & Time Interval | Publications | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theophylline | Theophylline | Human | Serum; Urine | Unchanged | pure compound | 12 | Healthy; M; Age= 18-30 y | 600 mg | Multiple | 5 days (one dose 8 h each) | 4,17±0,19 (SD) | 8,74±0,64 (SD) | 55,3 | (0-8h) | 6,06±0,38 (SD) | 5,13±5,13 | 30.8mg±2,9 (0-34 (h)) | Publications | |||
| Theophylline | Theophylline | Human | Plasma; Urine | Unchanged | solution with 100 mL water | pure compound | 21 | Healthy; 11 F; 10 M; Age= 18-23 y | 240 mg | Single | 1,10±0,7 (SD) | 8,7±2,7 (SD) | 4615 | (0-inf) | 137.6±40,1 mg (SD) ((0-24h)) | Publications | |||||
| Theophylline | Theophylline | Human | Serum; Urine | Unchanged | 15 mL elixir | pure compound | 6 | Healthy; M; Age= 24±1.06 y | 500 mg | Single | 107,5 | (0-inf) | 9,09±2,73 (SD) | 17,80±0,8 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Urine | Unchanged | with 100 mL water | pure compound | 4 | Healthy; 3 F; 1 M; Age= 24-33 y | 375 mg | Single | 13,40±1,5 (SD) | Publications | |||||||||
| Theophylline | Theophylline | Human | Serum; Urine | Unchanged | 15 mL elixir | pure compound | 6 | Healthy; M; Age= 24±1.06 y | 375 mg | Single | 99,06 | (0-inf) | 8,17±2,54 (SD) | 15,40±1,5 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Urine | Unchanged | tablets with 100 mL water | pure compound | 3 | Healthy; 2 M; 1 F; Age= 25.7±1.2 y | 375 mg | Single | 13,30±1,7 (SD) | Publications | |||||||||
| Theophylline | Theophylline | Human | Serum; Urine | Unchanged | 15 mL elixir | pure compound | 6 | Healthy; M; Age= 24±1.06 y | 250 mg | Single | 88,74 | (0-8h) | 7,38±1,97 (SD) | 14,70±2,1 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma; Urine | Unchanged | dissolved in 100 mL water | pure compound | 9 | Healthy; M; Age= 31.1 y | 200 mg | Single | 1,00 | 8 | 75,8 | (0-inf) | 7,58±1,34 (SD) | 9,80±5,4 (SD) | Publications | ||||
| Theophylline | Theophylline | Human | Serum | Unchanged | tablets | pure compound | 6 | 150 mg | Single | 1,20 | 4,55±0,19 (SEM) | 43,8 | (0-inf) | 6,58±0,23 (SEM) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | enteric coated tablet of aminophylline + 200 mL water | pure compound | 6 | Healthy; M; Age= 21±24 y | 200 mg | Single | 2,21±0,447 (SD) | 6364±0,587 (SD) | 40944 | (0-9h) | 7,985±0,769 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | solution | pure compound | 6 | Healthy; M; Age= 24±0.7 y | 200 mg | Single | 1,40±0,4 (SEM) | 11±1,2 (SEM) | 95 | (0-inf) | 6,4±0,9 (SEM) | Publications | |||||
| Theophylline | Theophylline | Human | Serum | Unchanged | dissolved in 200 mL orange juice | pure compound | 15 | Healthy; F; smokers; Age= 24.1±3.3 y | 0,004 g/Kg bw | Single | 2,00 | 6 | 5,13±1,09 (SD) | Publications | |||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | elixir + 200 mL water | pure compound | 11 | Healthy; smoking. 8 M; 3 F; Age= 63.1 ± 1.3 y | 0,005 g/Kg bw | Single | 1,02±0,25 (SD) | 12,39±1,76 (SD) | 112,1 | (0-inf) | 6,44±1,21 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Serum | Unchanged | elixir + 200 mL water | pure compound | 8 | Healthy; 6 M; 2 F; Age= 38.4 ± 7.9 y | 0,005 g/Kg bw | Single | 1,09±0,37 (SD) | 14,33±2,02 (SD) | 150,6 | (0-inf) | 8,14±1,23 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | dissolved in 150 mL water + food | pure compound | 8 | Healthy; 2 F; 6 M; Age= 22.6±1.6 y | 270 mg | Single | 4,40±0,75 (SD) | 5,47±0,83 (SD) | 73,5 | (0-inf) | 6,7±1,3 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Serum | Unchanged | elixir + 200 mL water | pure compound | 22 | Healthy; M; Age= <60 y | 0,005 g/Kg bw | Single | 1,08±0,24 (SD) | 12,86±1,73 (SD) | 110,81 | (0-inf) | 6,85±1,32 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Serum | Unchanged | elixir + 200 mL water | pure compound | 30 | Healthy; 22 M; 8 F; Age= 65.8 ±3.5 y | 0,005 g/Kg bw | Single | 1,12±0,22 (SD) | 12,99±1,86 (SD) | 114,99 | (0-inf) | 6,98±1,38 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | Nuelin tablets + 150 mL water | pure compound | 6 | Healthy; M; Age= 19-21 y | 250 mg | Single | 6,2±1,4 (SD) | Publications | |||||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | dissolved in 150 mL water | pure compound | 8 | Healthy; 2 F; 6 M; Age= 22.6±1.6 y | 270 mg | Single | 1,34±1,2 (SD) | 7,82±1,32 (SD) | 80,1 | (0-inf) | 6,3±1,4 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 7 | Healthy; M; CYP1A2 haplotype pair H1 | 200 mg | Single | 0,90±1,4 (SD) | 7,49±1,75 (SD) | 103,6 | (0-48h) | 13±1,4 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 6 | Healthy; M; CYP1A2 haplotype pair H4 | 200 mg | Single | 0,40±0,3 (SD) | 6,17±0,17 (SD) | 95,2 | (0-48h) | 14,8±1,4 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | elixir + 200 mL water | pure compound | 19 | Healthy; no smoking. 14 M; 5 F; Age= 68.6 ± 2.1 y | 0,005 g/Kg bw | Single | 1,08±0,04 (SD) | 13,49±2,04 (SD) | 116,66 | (0-inf) | 7,27±1,42 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Serum | Unchanged | tablets of aminophylline + 200 mL water | pure compound | 6 | Healthy; M; Age= 21±24 y | 200 mg | Single | 1,90±0,894 (SD) | 6886±0,97 (SD) | 45227 | (0-9h) | 8,448±1,42 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Serum | Unchanged | elixir + 200 mL water | pure compound | 8 | Healthy; F; Age= >60 y | 0,005 g/Kg bw | Single | 1,21±0,29 (SD) | 13,47±2,02 (SD) | 124,25 | (0-inf) | 7,35±1,57 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 7 | Healthy; M; CYP1A2 haplotype pair H2 | 200 mg | Single | 0,80±1 (SD) | 6,65±1,72 (SD) | 97,6 | (0-48h) | 14,9±1,6 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | sugar coated tablets of aminophylline + 200 mL water | pure compound | 6 | Healthy; M; Age= 21±24 y | 200 mg | Single | 2,00±0,707 (SD) | 7045±0,771 (SD) | 44639 | (0-9h) | 8,176±1,68 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 3 | Healthy; M; CYP1A2 haplotype pair H6 | 200 mg | Single | 1,00 | 7,7±0,64 (SD) | 115,5 | (0-48h) | 14,7±1,8 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | na | pure compound | 6 | Healthy; M; Age= 29-43 y | 250 mg | Single | 8,30±1,4 (SD) | 3,91±0,54 (SD) | 97,49 | (0-inf) | 9,2±2 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Serum | Unchanged | na + standard breakfast | pure compound | 6 | Healthy; M; Age= 29-43 y | 250 mg | Single | 9,30±1,7 (SD) | 3,83±0,69 (SD) | 95,57 | (0-inf) | 9,3±2,1 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | tablets at high fat/high protein regimen | pure compound | 12 | Healthy; M | 300 mg | Single | 9,08±2,23 | 5,37±1,48 (SD) | 116,65 | 10,03±2,25 | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | dissolved in 200 mL orange juice | pure compound | 12 | Healthy; F; non smokers; Age= 24.4±2.3 y | 0,004 g/Kg bw | Single | 2,00 | 6 | 7,76±2,39 (SD) | Publications | |||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | tablets + 200 mL water | pure compound | 6 | Healthy; M; Age= 21±24 y | 200 mg | Single | 2,00±0,707 (SD) | 6040±0,509 (SD) | 36512 | (0-9h) | 7,308±2,683 (SD) | Publications | |||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 8 | Healthy; M; CYP1A2 haplotype pair H5 | 200 mg | Single | 0,70±0,3 (SD) | 6,12±1,45 (SD) | 93 | (0-48h) | 14,6±3,1 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | sugar-coated tablets with 100-200 mL water | pure compound | 12 | Healthy; M; Age= 23.9 y | 600 mg | Multiple | 4 days (one dose at morning, one dose at afternoon and one dose at evening) | 1,00 | 8,11±2,49 (SD) | 50 | (0-8h) | 7,41±3,22 (SD) | Publications | ||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | tablets at high fat diet regimen | pure compound | 12 | Healthy; M | 300 mg | Single | 8,83±1,8 | 4,5±1,2 (SD) | 115,01 | 12,23±4,02 | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 6 | Healthy; M; CYP1A2 haplotype pair H3 | 200 mg | Single | 0,50±0,1 (SD) | 6,78±1,53 (SD) | 100,1 | (0-48h) | 14±4,2 (SD) | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | tablets at normal diet regimen | pure compound | 12 | Healthy; M | 300 mg | Single | 7,92±1,62 | 4,53±1,32 (SD) | 115,01 | 14,12±5,65 | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | tables + 150 mL water | pure compound | 12 | Healthy; M | 300 mg | Single | 7,50±2,84 | 3,85±1,35 (SD) | 105,8 | 13,67±5,99 | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 8 | Healthy; 4 M; 4 F; Age= 29.7±0.3 y; Caucasians | 375 mg | Multiple | 3 days (1 dose every 8 hours) | 3,00 | 10 | 64,5 | (0-8 h) | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | pure compound | 9 | Healthy; 4 M; 5 F; Age= 30.3±0.4 y; Caucasians | 375 mg | Multiple | 3 days (1 dose every 8 hours) | 2,00 | 6 | 38,1 | (0-8 h) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | extended-release capsules | pure compound | 18 | 900 mg | Multiple | 5 days (one dose at evening) | 10,20±3 (SD) | 10,7±4,3 (SD) | 209 | (0-24h) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | extended-release capsules | pure compound | 18 | 900 mg | Multiple | 5 days (one dose at morning) | 7,00±3,4 (SD) | 10,5±3,7 (SD) | 210 | (0-24h) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | sustained-release tablet + 200 mL water | pure compound | 8 | Healthy; 6 M; 2 F; Age= 38.4 ± 7.9 y | 100 mg | Single | 8,25±1,98 (SD) | 11,81±4,52 (SD) | 194,3 | (0-inf) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | sustained-release tablet + 200 mL water | pure compound | 19 | Healthy; no smoking. 14 M; 5 F; Age= 68.6 ± 2.1 y | 100 mg | Single | 7,36±1,34 (SD) | 7,49±1,74 (SD) | 122,95 | (0-inf) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | sustained-release tablet + 200 mL water | pure compound | 22 | Healthy; M; Age= <60 y | 100 mg | Single | 7,27±1,32 (SD) | 7,51±1,68 (SD) | 120,9 | (0-inf) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | sustained-release tablet + 200 mL water | pure compound | 30 | Healthy; 22 M; 8 F; Age= 65.8 ±3.5 y | 100 mg | Single | 7,46±1,28 (SD) | 7,29±1,53 (SD) | 117,75 | (0-inf) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | sustained-release tablet + 200 mL water | pure compound | 8 | Healthy; F. Age= >60 y | 100 mg | Single | 8,25±1,28 (SD) | 6,68±0,74 (SD) | 109,09 | (0-inf) | Publications | ||||||
| Theophylline | Theophylline | Human | Serum | Unchanged | sustained-release tablet + 200 mL water | pure compound | 11 | Healthy; smoking. 8 M; 3 F; Age= 63.1 ± 1.3 y | 100 mg | Single | 7,45±0,93 (SD) | 7,11±1,13 (SD) | 108,76 | (0-inf) | Publications | ||||||
| Theophylline | Theophylline | Human | Plasma | Unchanged | with 4 oz tap water | pure compound | 3 | Healthy; M | 600 mg | Single | 2,00±2 (SD) | 15,32±1,44 (SD) | 207 | (0-48h) | Publications |